SherrardD.J., HerczG., PeiY., MaloneyN.A., GreenwoodC., ManuelA.The spectrum of bone disease in end stage renal failure. An evolving disorder.Kidney Int1993; 43: 436–42.
2.
RosenquistC., FledeliusC., ChristgauS., PedersenB.J., BondeM., QvistP.Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen.Clin Chem1998; 44: 2281–9.
3.
StepanJ., LachmanovaJ., StrakovaM., PacovskyV.Serum osteocalcin, bone alkaline phosphatase isoenzyme and plasma tartrate resistant acid phosphatase in patients on chronic maintenance hemodialysis.Bone Miner1987; 3: 177–83.
4.
RobinsS.P., WoitgeH., HesleyR., JuJ., SeyedinS., SeibelM.J.Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption.J Bone Miner Res1994; 9: 1643–9.
5.
ChristgauS., RosenquistC., AlexandresenP., BjarnsonN.H., RavnP., FledeliusC.Clinical evaluation of serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides.Clin Chem1998; 44: 2290–300.
6.
ChristgauS., Bitsch–JensenO., Hanover BjarnasonN., Gamwell HenriksenE., QvistP., AlexandresenP.Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy.Bone2000; 26: 505–11.
7.
CouttenyeM.M., D'HaeseP.C., DengT.J., Van HoofV.O., VerpootenG.A., De BroeM.E.High prevalence of adynamic bone disease diagnosed by biochemical markers in a wide sample of European CAPD population.Nephrol Dial Transplant1997; 12: 2144–50.
8.
MalyszkoJ., WotczyriskiS., ZbrochE., BrzoskoS., MalyszkoJ., MysliwiecM.Serum CrossLaps correlations with serum ICTP and urine DPD in hemodialyzed and peritoneally dialyzed patients.Nephron2001; 87: 283–5.
